Healthcare SPAC Eucrates Biomedical Acquisition prices $100 million IPO at $10

Eucrates Biomedical Acquisition, a blank check company formed by Vedanta Management targeting data-driven healthcare and biotech businesses, raised $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50.

The company is led by Chairman Stelios Papadopoulos, who is the Chairman of Biogen, Exelixis, and Regulus Therapeutics and also co-founder of Anadys Pharmaceuticals (acquired in 2011) and Cellzone (acquired in 2012). He is joined by CEO and Director Parag Saxena, the co-founder and CEO of private equity investment management firms Vedanta Management and New Silk Route Advisors. The SPAC plans to target North American and European healthcare companies, specifically those utilizing biomedicine and data science.

Eucrates Biomedical Acquisition plans to list on the Nasdaq under the symbol EUCRU. Stifel and H.C. Wainwright acted as joint bookrunners on the deal.

The article Healthcare SPAC Eucrates Biomedical Acquisition prices $100 million IPO at $10 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest IPOs Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More